Hims & Hers Health has made a significant move in the Canadian pharmaceutical landscape by announcing its intent to offer generic semaglutide, a key player in the weight loss medication market, as the patent held by Novo Nordisk for its branded versions, Ozempic and Wegovy, is set to expire in January. This development not only marks Hims & Hers’ debut in Canada but also represents a pivotal moment for affordable healthcare solutions in the region.
Andrew Dudum, co-founder and CEO of Hims & Hers, emphasized the potential of this venture, stating, “Canada is a major opportunity to show what affordable, high-quality weight loss care can look like.” The company aims to combine accessibility with personalized care, a strategy that reflects a growing demand for cost-effective treatment options in the wake of increasing obesity rates, which affect nearly 1 in 4 Canadians, according to the Canadian Obesity Network.
Generic semaglutide is expected to revolutionize the market, as generics are designed to match the efficacy of brand-name drugs while adhering to the same rigorous safety standards. This is particularly important as the Canadian semaglutide market generated an impressive revenue of $1.18 billion in 2024 and is projected to soar to $4.03 billion by 2035, as noted by market research firm Grand View Research. However, it is crucial to highlight that, despite the promising figures, no generic version of semaglutide has yet been approved by Health Canada. The approval process is ongoing, with Sandoz, a leading name in generics, already in the queue for regulatory approval.
The announcement from Hims & Hers follows a series of strategic shifts, including the recent acquisition of the European telehealth platform Zava, which expands its reach to Ireland, France, and Germany. This move indicates a broader vision of integrating telehealth services with pharmaceutical offerings to provide comprehensive health solutions.
Interestingly, the lapse of Novo Nordisk’s patent can be traced back to a series of administrative oversights. The company failed to pay its annual maintenance fee for the patent in 2018, leading to a cascade of events that culminated in the loss of exclusivity. Canadian authorities confirmed that once a patent lapses, it cannot be revived, creating a vacuum that Hims & Hers and other pharmaceutical companies are eager to fill.
The competitive landscape has also shifted, as Novo Nordisk faces challenges from Eli Lilly’s Zepbound, another weight loss treatment that has gained traction in the U.S. market. This competitive pressure might have influenced Novo Nordisk’s decision-making regarding its patent strategy, as noted by a company spokesperson who remarked that intellectual property decisions are “carefully considered.”
David Meinertz, general manager of Hims & Hers’ international business, underscored the broader implications of making affordable obesity treatment accessible in Canada, stating, “Making affordable, holistic obesity treatment accessible has the potential to help strengthen the local healthcare system and unlock the potential for millions of Canadians to live healthier, more fulfilling lives.”
As Hims & Hers prepares to roll out generic semaglutide, the company is not just entering a new market; it is setting the stage for a potential transformation in how weight loss treatments are approached in Canada. With a focus on affordability and personalized care, it aims to address a critical healthcare need while navigating a complex regulatory environment. The success of this initiative could serve as a blueprint for other companies looking to innovate in the telehealth and pharmaceuticals space, ultimately benefiting patients who seek effective and affordable treatment options.
